知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.021 秒)

    Pharmaceutical formulation
    1.
    发明授权
    Pharmaceutical formulation 有权
    药物制剂

    公开(公告)号：US08618157B2

    公开(公告)日：2013-12-31

    申请号：US13000291

    申请日：2009-02-04

    申请人： Brett Antony Mooney ,  Panagiotis Keramidas

    发明人： Brett Antony Mooney ,  Panagiotis Keramidas

    IPC分类号： A61K31/405

    CPC分类号： A61K31/192 ,  A61K9/2027 ,  A61K9/2077 ,  A61K31/4045 ,  A61K45/06 ,  A61K2300/00

    摘要： A pharmaceutical composition comprising: a) a 5-HT1 agonist; b) an NSAID; and c) a disintegrant characterised in that the disintegrant comprises between about 15 to about 50% w/w based on the weight of the composition, said composition optionally comprising one or more other pharmaceutically acceptable excipients.

    摘要翻译： 一种药物组合物，其包含：a）5-HT1激动剂; b）NSAID; 和c）崩解剂，其特征在于，崩解剂基于组合物的重量包含约15至约50％w / w，所述组合物任选地包含一种或多种其它药学上可接受的赋形剂。

    Dosage Form Containing Two or More Active Pharmaceutical Ingredients in Different Physical Forms
    4.
    发明申请
    Dosage Form Containing Two or More Active Pharmaceutical Ingredients in Different Physical Forms 有权
    含有两种或多种不同物理形式的活性药物成分的剂型

    公开(公告)号：US20100092549A1

    公开(公告)日：2010-04-15

    申请号：US12526326

    申请日：2008-02-11

    申请人： Sandra Blundell ,  Panagiotis Keramidas ,  Brett Antony Mooney ,  Todd James Rutherford

    发明人： Sandra Blundell ,  Panagiotis Keramidas ,  Brett Antony Mooney ,  Todd James Rutherford

    IPC分类号： A61K9/48 ,  A61K31/5513

    CPC分类号： A61K9/4866 ,  A61K9/2018 ,  A61K9/2072 ,  A61K9/5084 ,  A61K31/135 ,  A61K31/551

    摘要： A dosage form for administration of two or more active pharmaceutical ingredients to a subject, comprising a first pharmaceutical composition comprising a first active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a first physical form selected from the group consisting of powder, granule, pellet, bead or mini-tablet form, and at least a second pharmaceutical composition comprising a second active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a second physical form selected from the group consisting of granule, pellet, bead, mini-tablet or tablet form, wherein the composition is characterised in that said first and second physical forms are selected to be different to minimise interactions between said first and second pharmaceutical compositions and to allow separation of said first and second pharmaceutical compositions for analysis on the basis of size difference.

    摘要翻译： 用于向受试者施用两种或更多种活性药物成分的剂型，其包含第一药物组合物，所述第一药物组合物包含第一活性药物成分和任选的一种或多种药学上可接受的赋形剂，所述第一物理形式选自粉末，颗粒， 丸剂，珠粒或迷你片剂形式，以及至少第二药物组合物，其包含第二活性药物成分和任选的一种或多种药学上可接受的赋形剂，所述第二物理形式选自颗粒，丸粒，珠粒，迷你片 或片剂形式，其中所述组合物的特征在于，所述第一和第二物理形式被选择为不同以使所述第一和第二药物组合物之间的相互作用最小化，并允许基于尺寸分离所述第一和第二药物组合物用于分析 区别。

    Process to control particle size
    5.
    发明授权
    Process to control particle size 有权
    控制粒度的过程

    公开(公告)号：US09034381B2

    公开(公告)日：2015-05-19

    申请号：US12093045

    申请日：2006-11-10

    申请人： Brett Antony Mooney ,  Panagiotis (Peter) Keramidas

    发明人： Brett Antony Mooney ,  Panagiotis (Peter) Keramidas

    IPC分类号： A61K9/14

    CPC分类号： A61K9/14

    摘要： A multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of: passing the pharmaceutical substance through a first stage of a particle size reduction process with a first set of particle size control parameters to obtain a feedstock of reduced median particle size and lesser distribution of median particle size for a second stage of a particle size reduction process; passing the feedstock, through a second stage of a particle size reduction process with a second set of particle size control parameters; optionally, using the product of the second stage or subsequent stages as a feedstock in further stages of a multi-stage particle size reduction process with a set of particle size control parameters for each stage; and collecting a pharmaceutical substance with a median particle size greater than 10 μm and with a narrow, reproducible distribution of median particle sizes.

    摘要翻译： 用于控制药物物质的粒径的多阶段方法包括以下步骤：使第一组粒度控制参数通过药物物质通过第一阶段的粒径减小过程，以获得减少的中值粒子的原料 颗粒尺寸减小过程的第二阶段的中值粒度的大小和较小的分布; 使原料通过具有第二组粒度控制参数的粒径减小过程的第二阶段; 任选地，使用第二阶段或后续阶段的产物作为进料，在多阶段粒径减小过程的进一步阶段中，每一阶段具有一组粒度控制参数; 并收集中值粒径大于10μm的药物物质，并具有中等粒径分布窄的可重复分布。

    Dosage form containing two or more active pharmaceutical ingredients in different physical forms
    9.
    发明授权
    Dosage form containing two or more active pharmaceutical ingredients in different physical forms 有权
    含有两种或多种不同物理形式的活性药物成分的剂型

    公开(公告)号：US09095519B2

    公开(公告)日：2015-08-04

    申请号：US12526326

    申请日：2008-02-11

    申请人： Sandra Blundell ,  Panagiotis Keramidas ,  Brett Antony Mooney ,  Todd James Rutherford

    发明人： Sandra Blundell ,  Panagiotis Keramidas ,  Brett Antony Mooney ,  Todd James Rutherford

    IPC分类号： A61K9/48 ,  A61K9/20 ,  A61K9/50 ,  A61K31/135 ,  A61K31/551

    CPC分类号： A61K9/4866 ,  A61K9/2018 ,  A61K9/2072 ,  A61K9/5084 ,  A61K31/135 ,  A61K31/551

    摘要： A dosage form for administration of two or more active pharmaceutical ingredients to a subject, comprising a first pharmaceutical composition comprising a first active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a first physical form selected from the group consisting of powder, granule, pellet, bead or mini-tablet form, and at least a second pharmaceutical composition comprising a second active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a second physical form selected from the group consisting of granule, pellet, bead, mini-tablet or tablet form, wherein the composition is characterized in that said first and second physical forms are selected to be different to minimize interactions between said first and second pharmaceutical compositions and to allow separation of said first and second pharmaceutical compositions for analysis on the basis of size difference.

    摘要翻译： 用于向受试者施用两种或更多种活性药物成分的剂型，其包含第一药物组合物，所述第一药物组合物包含第一活性药物成分和任选的一种或多种药学上可接受的赋形剂，所述第一物理形式选自粉末，颗粒， 丸剂，珠粒或迷你片剂形式，以及至少第二药物组合物，其包含第二活性药物成分和任选的一种或多种药学上可接受的赋形剂，所述第二物理形式选自颗粒，丸粒，珠粒，迷你片 或片剂形式，其中所述组合物的特征在于，所述第一和第二物理形式被选择为不同以使所述第一和第二药物组合物之间的相互作用最小化，并允许基于尺寸分离所述第一和第二药物组合物用于分析 区别。

    PROCESS TO CONTROL PARTICLE SIZE
    10.
    发明申请
    PROCESS TO CONTROL PARTICLE SIZE 有权
    控制颗粒尺寸的过程

    公开(公告)号：US20090220609A1

    公开(公告)日：2009-09-03

    申请号：US12093045

    申请日：2006-11-10

    申请人： Brett Antony Mooney ,  Panagiotis Peter Keramidas

    发明人： Brett Antony Mooney ,  Panagiotis Peter Keramidas

    IPC分类号： A61K9/14 ,  A61K31/55

    CPC分类号： A61K9/14

    摘要： A multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of: passing the pharmaceutical substance through a first stage of a particle size reduction process with a first set of particle size control parameters to obtain a feedstock of reduced median particle size and lesser distribution of median particle size for a second stage of a particle size reduction process; passing the feedstock, through a second stage of a particle size reduction process with a second set of particle size control parameters; optionally, using the product of the second stage or subsequent stages as a feedstock in further stages of a multi-stage particle size reduction process with a set of particle size control parameters for each stage; and collecting a pharmaceutical substance with a median particle size greater than 10 μm and with a narrow, reproducible distribution of median particle sizes.

    摘要翻译： 用于控制药物物质的粒径的多阶段方法包括以下步骤：使第一组粒度控制参数通过药物物质通过第一阶段的粒径减小过程，以获得减少的中值粒子的原料 颗粒尺寸减小过程的第二阶段的中值粒度的大小和较小的分布; 使原料通过具有第二组粒度控制参数的粒径减小过程的第二阶段; 任选地，使用第二阶段或后续阶段的产物作为进料，在多阶段粒径减小过程的进一步阶段中，每一阶段具有一组粒度控制参数; 并收集中值粒径大于10微米的药物物质，并具有中等粒径分布窄的可重复分布。